Caduet pills make their way through the manufacturing process at one of Pfizer’s manufacturing facilities. Photo: Bloomberg

Caduet has annual sales of $339 million in the US, Ranbaxy said in a statement.

The terms of the agreement were not disclosed.

Ranbaxy, majority-owned by Japan’s Daiichi Sankyo, last week launched a generic version of Lipitor, the world’s top selling drug, which is also a Pfizer brand.